Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023
Share
Sinphar Pharmaceutical Co.,Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 727.59 million compared to TWD 716.21 million a year ago. Net income was TWD 109.04 million compared to TWD 87.21 million a year ago. Basic earnings per share from continuing operations was TWD 0.65 compared to TWD 0.52 a year ago. Diluted earnings per share from continuing operations was TWD 0.65 compared to TWD 0.52 a year ago.
For the six months, sales was TWD 1,498.61 million compared to TWD 1,385.02 million a year ago. Net income was TWD 189.16 million compared to TWD 145.3 million a year ago. Basic earnings per share from continuing operations was TWD 1.13 compared to TWD 0.87 a year ago. Diluted earnings per share from continuing operations was TWD 1.13 compared to TWD 0.87 a year ago.
Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Companyâs principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.